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Objective: Our objective was to examine the mechanisms via which exenatide attenuates post-
prandial hyperglycemia in type 2 diabetes mellitus (T2DM).
Study Design: Seventeen T2DM patients (44 yr; seven females, 10 males; body mass index  33.6
kg/m2; glycosylated hemoglobin  7.9%) received a mixed meal followed for 6 h with double-
tracer technique ([1-14C]glucose orally; [3-3H]glucose iv) before and after 2 wk of exenatide. In
protocol II (n 5), but not in protocol I (n 12), exenatide was given in themorning of the repeat
meal. Total and oral glucose appearance rates (RaT and RaO, respectively), endogenous glucose
production (EGP), splanchnic glucose uptake (75 g  RaO), and hepatic insulin resistance (basal
EGP  fasting plasma insulin) were determined.
Results:After2wkofexenatide (protocol I), fastingplasmaglucosedecreased (from10.2 to7.6mM)
and mean postmeal plasma glucose decreased (from 13.2 to 11.3 mM) (P  0.05); fasting and
meal-stimulated plasma insulin and glucagon did not change significantly. After exenatide, basal
EGP decreased (from 13.9 to 10.8 mol/kg  min, P 0.05), and hepatic insulin resistance declined
(both P  0.05). RaO, gastric emptying (acetaminophen area under the curve), and splanchnic
glucose uptake did not change. In protocol II (exenatide given before repeatmeal), fasting plasma
glucose decreased (from 11.1 to 8.9 mM) andmean postmeal plasma glucose decreased (from 14.2
to 10.1 mM) (P  0.05); fasting and meal-stimulated plasma insulin and glucagon did not change
significantly. After exenatide, basal EGP decreased (from 13.4 to 10.7mol/kg  min, P 0.05). RaT
and RaO decreased markedly from 0–180 min after meal ingestion, consistent with exenatide’s
action to delay gastric emptying.
Conclusions: Exenatide improves 1) fasting hyperglycemia by reducing basal EGP and 2) postmeal
hyperglycemia by reducing the appearance of oral glucose in the systemic circulation. (J Clin
Endocrinol Metab 96: 1763–1770, 2011)
Individuals with type 2 diabetes mellitus (T2DM) arecharacterized by defects in insulin secretion, peripheral
(muscle) glucose uptake, suppression of endogenous (he-
patic) glucose production (EGP), and splanchnic (primar-
ily hepatic) glucose uptake (SGU) (1). It follows that in-
terventions that reverse specific pathogenic abnormalities
in T2DM are most likely to exert beneficial and durable
effects to improve glycemic control. Glucagon-like pep-
tide-1 (GLP-1) receptor agonists represent a new class of
antidiabetic agents that have gainedwidespread use (2, 3).
In T2DM, there is both deficiency of GLP-1 (4, 5) and
-cell resistance to the stimulatory effect of GLP-1 on in-
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sulin secretion (6). Treatment of T2DM patients with
GLP-1 receptor agonists augments insulin secretion and
inhibits glucagon release, leading to reductions in both
fasting and postprandial plasma glucose concentrations
(7–10). However, no previous study has examined the
physiological mechanisms via which chronic treatment
with GLP-1 receptor agonists improve glucose homeosta-
sis in humans with T2DM.
After mixed meal ingestion, acute iv exenatide admin-
istration in T2DMmarkedly reduces the postmeal plasma
glucose excursion by inhibiting EGP and delaying gastric
emptying (8). Approximately half of the decline in EGP
was due to inhibition of glucagon secretion and half was
due to increased insulin secretion (8). Because gastric emp-
tyingwas inhibited, an effect of exenatide to augment SGU
could not be examined. A single dose of the dipeptidyl
peptidase-4 inhibitor vildagliptin, which increased endog-
enous GLP-1 levels in T2DM subjects, also reduced post-
meal plasma glucose concentration in association with in-
creased plasma insulin and decreased plasma glucagon
concentrations and a decrease in EGP; no effect on pe-
ripheral tissue insulin sensitivity or gastric emptying was
observed (11). In rodents, GLP-1 receptors are expressed
onnerve terminals in theportal circulation and function to
augment hepatic glucose uptake (HGU) in response to
elevatedportal veinGLP-1 levels (12, 13). EnhancedHGU
also has been demonstrated after acute portal vein GLP-1
administration in dogs (14–16).
Despite their introduction into the clinical market for
the treatment of T2DMover 6 yr ago, no study inman has
examined the effect of chronicGLP-1 receptor agonists on
the physiologicalmechanisms viawhich they improve glu-
cose homeostasis after meal ingestion. The present study
was undertaken to 1) provide qualitative/quantitative in-
formation about the physiologicalmechanisms [enhanced
suppression of hepatic glucose production (HGP), in-
creased peripheral tissue glucose disposal, increased SGU,
and altered glucose absorption rate] responsible for im-
provedpostprandial hyperglycemia (mixedmeal) after ex-
enatide administration in T2DM individuals and 2) con-
trast the effect of chronic (2 wk) exenatide administration
when exenatide is given vs. not given in the morning of
study. Because exenatide administration before the meal
produced physiological changes that closely paralleled
those after acute iv exenatide (8), we enrolled more sub-
jects in the protocol in which exenatide was not adminis-
tered immediately before the meal to examine whether
there was a long-lasting effect of the exenatide adminis-
tered on the previous day.
Subjects and Methods
Subjects
Seventeen T2DM (43  2 yr; seven females, 10 males; body
mass index  33.8  1.5 kg/m2; glycosylated hemoglobin 
7.9 0.4%; diabetes duration 6 4 yr)without glutamic acid
decarboxylase (GAD65) antibodies or diabetic complications
received meal tolerance test (MTT) before and after 2 wk of
exenatide. Subjectswere ingoodhealthasdeterminedbymedical
history, physical exam, screening blood tests, urinalysis, and
electrocardiogram.Diabetes was treatedwithmetformin (five in
protocol I, two in protocol II), sulfonylurea (three in protocol I,
two in protocol II), metformin/sulfonylurea (one in protocol I,
one in protocol II), or diet (three in protocol I, none in protocol
II).Oral hypoglycemic agentswere not given on the day of study.
No subject was taking any other medication known to affect
glucose metabolism. Body weight was stable (within1 kg) for
6months before study. No subject participated in any strenuous
exercise program. The study was approved by the Institutional
Review Board at the University of Texas Health Science Center
at SanAntonio, and informedwritten consentwasobtained from
each subject before participation.
Study design
Subjects participated in two protocols that were identical
with one exception. After the baseline MTT, subjects were
treated with exenatide for 2 wk, at which time the MTT was
repeated. In protocol I, on the morning of the repeat MTT (n
12) subjectsdidnot take exenatide; inprotocol II (n5), subjects
received their usual exenatide dose in the morning of the repeat
MTT. Subjects in both protocols I and II continued to take their
regularoral antidiabeticmedication excepton themorningof the
MTT. At screening, subjects received dietary guidance to con-
sume a weight-maintaining diet (50% carbohydrate, 30% pro-
tein, 20% fat).
MTT with double tracer
Subjects reported to theClinicalResearchCenter of theTexas
Diabetes Institute at 0700 h after a 10-h overnight fast. A cath-
eter was inserted into an antecubital vein, and a prime [25Ci
fasting plasma glucose (FPG)/100[ and continuous (0.25 Ci/
min) [3-3H]glucose infusion was started and maintained for the
entire study (9 h). A second catheter was inserted retrogradely
into a vein on the dorsum of the hand, which was placed in a
thermo-regulated box (70 C) for blood sampling. At 0930 h,
blood samples were obtained at30,20,10,5, and 0 min
for FPG, insulin, glucagon, and acetaminophen concentrations
and plasma tritiated glucose radioactivity. At time zero (1000 h),
subjects voided and ingested a standardizedmeal containing75g
glucose, 25 g fat, and 20 g protein. There was no other carbo-
hydrate source in the meal. The solid component of the meal
contained 600 kcal, madewith eggs and cheese. The oral glucose
load was mixed with 100 Ci 1-14C-labeled glucose and 1000
mg acetaminophen elixir (protocol I only) to monitor gastric
emptying (17). Patients consumed the meal within 15 min, and
blood was obtained every 15–30 min for plasma [14C/3H]glucose
specific activities and plasma glucose, insulin, glucagon,C-peptide,
and acetaminophen concentrations.Upon study termination, urine
was collected and glucose concentration measured.
On the day after MTT, subjects self-administered exenatide,
5 g sc before breakfast and dinner, for 7 d. Exenatide was
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increased to 10 g sc twice daily for the subsequent 7 d (14 d of
therapy). In protocol II, exenatide was injected sc 15 min before
meal ingestion. In protocol I, the last exenatide dosewas given at
1800 h on the evening before the repeatMTT; no exenatide was
given on the morning of the MTT.
Analytical determinations
Plasma glucosewas determinedwith glucose oxidase (Beckman
Glucose Analyzer, Fullerton, CA). Plasma insulin, C-peptide, and
glucagonconcentrationsweremeasuredbyRIA (Diagnostics Prod-
ucts Corp., Los Angeles, CA). Plasma acetaminophen was deter-
mined by liquid chromatography spectrometry (PPDLaboratories,
Middleton, WI). Plasma [3H]glucose and [14C]glucose radioactiv-
ity was determined on barium hydroxide/zinc sulfate-precipitated
plasma extracts.
Calculations
In the postabsorptive state, steady-state conditions prevail
and EGP (equals rate of total-body glucose disposal) was mea-
sured as [3-3H]glucose infusion rate (decay per minute) 
steady-state plasma [3-3H]glucose specific activity (decay per
milligram). After glucose ingestion, non-steady-state conditions
prevail and rate of total glucose appearance (RaT) and rate of
glucose disappearance (Rd) were computed from [3-3H]glucose
data using Steele’s two-compartment model. Glucose clearance
was calculated as Rd divided by plasma glucose concentration.
To calculate the rate of oral glucose appearance (RaO),
[1-14C]glucose plasma radioactivity was divided by the specific
activity of the glucose drink to calculate the plasma oral glucose
concentration that would be attained in the systemic circulation
if the sole source of glucose was the oral load and by subtracting
the plasma endogenous glucose concentration. The calculated
endogenous glucose concentration and [3-3H]glucose data were
then used to compute EGP in peripheral plasma. RaO was ob-
tained as the difference between total and endogenous glucose
appearance rates (18). Splanchnic (represents hepatic plus gas-
trointestinal tissues) glucose uptake was calculated as the differ-
ence between ingested glucose (75 g) and RaO.
Hepatic insulin resistance index (HIRI) was calculated as
baseline EGP (milligrams per kilogram per minute)  fasting
plasma insulin (picomoles per liter) (19). Insulin secretory rate
was calculated by plasma C-peptide deconvolution (20). -Cell
function was assessed by dividing the insulin secretory rate (pi-
comoles per kilogram per minute) by plasma glucose concentra-
tion (milligrams per deciliter) (21). Insulin secretion/insulin re-
sistance (disposition) index was calculated as [ area under the
curve (AUC)-insulin secretory rate (ISR)/AUC-glucose]Mat-
suda index of insulin sensitivity (21, 22).
Statistics
Differences between metabolic parameters (plasma glucose,
insulin, C-peptide, glucagon, glucose kinetic measurements,
HIR, and indices of-cell function)before andafterMTTstudies
were compared using ANOVAwith repeatedmeasures and time
course during the MTT. Significant differences were confirmed
withaBonferroni test.Differencesbetweenbaseline (fasting) and
postmeal values within protocol I and within protocol II were
compared using paired t test. P value 0.05 was considered
significant. Data are presented as mean  SE.
Results
Because no differences in any clinical, laboratory. or
metabolic parameters were noted between metformin-
and sulfonylurea-treated subjects in protocols I and II,
data from all subjects were combined for analysis. Body
weight did not change after 2 wk of exenatide in either
protocol I or II [93.9 3.7 to 93.3 3.7 kg, P value not
significant (NS)].
Protocol I
Plasmaglucose, insulin, andglucagonconcentrations
and insulin secretion and insulin sensitivity indices
FPGwas 10.20.8mmol/liter and increased to 13.2
0.8 mmol/liter (mean, 0–360 min) during the preex-
enatideMTT (Table 1 andFig. 1). After 2wkof exenatide,
FPG decreased to 7.6 0.7 mmol/liter, and mean plasma
glucose (0–360 min) during MTT declined to 11.3 0.7
mol/liter (both P 0.005, pre vs. post) (Table 1 and Fig.
1). After exenatide treatment, FPI decreased from 61 6
to 46  6 pmol/liter (P value NS) (Table 1 and Fig. 1),
and the mean plasma insulin from 0–360 min increased
slightly from 122  16 to 150  20 pmol/liter (Table 1
and Fig. 1). Both fasting and mean postmeal plasma glu-
cagon concentration did not change significantly after ex-
enatide (Table 1).
The fasting insulin secretory rate tended to increase (P
value NS), whereas the ISR during the meal (1665 151
to1951120pmol/min,P0.01) increased significantly
after exenatide. The insulin secretion/insulin resistance
(disposition) index during MTT performed after ex-
enatide increased by 69% from 563 126 to 951 167
(P  0.04) (Table 1).
TheMatsuda index of insulin sensitivity duringMTT
tended to increase after exenatide (4.0  0.5 to 5.4 
0.6), but the increase did not reach significance. The
mean glucose clearance (0–360 min) did not change
(Table 1).
Glucose kinetics (Table 1)
Neither the RaT nor the RaO (Table 1) in the systemic
circulation after the meal was changed after 2 wk of ex-
enatide.After exenatide for2wk,basalEGPdeclined from
13.4 1.5 to 10.7 0.8mol/kg  min (P 0.05) (Table
1), and the decrement in basal EGP correlated closelywith
the decrement in FPG (r  0.70; P  0.01). After 14 d of
exenatide, the mean rate of EGP during the meal did not
change (4.0  0.8 to 4.3  0.9, P  0.60) (Table 1).
The appearance of acetaminophen (AUC) in the sys-
temic circulation over the 0–360 min after the meal was
similar in the meal test performed before (1481 22 g/
ml) and after (1487 49g/ml) exenatide (Supplemental
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Fig. 1, published on The Endocrine Society’s Journals On-
line web site at http://jcem.endojournals.org). This indi-
cates that gastric emptying of ingested glucose was com-
plete andwas not alteredwhen the last exenatide dosewas
given in the evening before the meal. SGU was similar in
the preexenatide (63.75.4 g) and postexenatide (62.7
4.4 g) studies. Urinary glucose excretion during MTT de-
clined significantly after exenatide (Table 1).
Protocol II
Plasma glucose, insulin, and glucagon, and insulin
secretory indices
FPGwas 11.1 0.6 nmol/liter and increased to 14.2
0.6mol/liter (mean, 0–360min) during the preexenatide
MTT (Table 1 and Fig. 1). After 2 wk of exenatide, FPG
decreased to 8.9 0.5 nmol/liter (P 0.05) andmean PG
during MTT declined to 10.1  0.3 nmol/liter (P  0.05
TABLE 1. Clinical and metabolic parameters at baseline and after 2 wk of exenatide treatment
Protocol I, no exenatide Protocol II, with exenatide
P value
(protocol I vs. II)Pre Post
P value
(pre vs. post) Pre Post
P value
(pre vs. post)
Number 12 5
Age (yr) 42  2 46  4
Gender (male/female) 8/4 2/3
Weight (kg) 95.8  4.5 95.1  4.5 89.4  6.8 89.0  6.7 NS
BMI (kg/m2) 33.3  1.3 33.1  1.3 34.4  3.8 34.2  3.7 NS
HbA1c (%) 9.1  0.7 9.4  0.7 0.0005
Fasting
Plasma glucose (nmol/liter) 10.2  0.8 7.6  0.7 0.0001 11.1  0.6 8.9  0.5 0.04 NS
Plasma insulin (pmol/liter) 61  6 46  6 73  22 88  39 NS
Plasma glucagon (pg/liter) 68  6 75  8 47  7 54  7 NS
EGP (mol/kg  min) 13.9  0.8 10.8  0.6 0.0005 13.4  1.5 10.7  0.8 0.05 NS
ISR (pmol/min) 498  51 581  71 341  46 434  47 NS
HIRI (mol/kg  min 
pmol/liter)
852  97 492  59 0.01 1105  479 1016  515 0.69 NS
Glucose clearance
(ml/kg  min)
1.5  0.1 1.5  0.2 1.4  0.3 1.2  0.1 NS
Mixed meal
Plasma glucose (nmol/liter),
0–360 min
13.2  0.8 11.3  0.7a 0.0001 14.2  0.6 10.1  0.3a 0.04
Plasma insulin (pmol/liter),
0–360 min
122  16 150  20a 0.04 127  33 148  23 NS
Plasma glucagon
(pmol/liter), 0–360 min
68  6 72  5 53  6 51  9 NS
EGP (mol/kg  min), 0–360
min
5.5  0.7 4.4  0.7 4.0  0.8 4.3  0.9 NS
0–180 min 6.3  1.0 4.9  0.8 3.9  1.0 4.7  1.2 NS
180–360 min 4.7  0.5 4.0  0.6 4.1  0.6 3.9  0.7 NS
RaO (mol/kg  min), 0–360
min
10.7  1.3 10.4  1.0 12.4  0.9 10.2  1.1 0.12
0–180 min 16.2  1.7 16.8  1.3 19.8  1.2 9.5  3.5 0.05 0.002
180–360 min 5.1  1.7 4.0  0.7 5.0  0.8 10.9  3.4 0.05 0.008
RaT (mol/kg  min), 0–360
min
17.0  1.1 15.3  0.9 0.10 16.4  1.4 14.5  1.2 0.10 NS
0–180 min 23.8  1.1 22.6  1.1 23.7  1.8 14.3  2.5 0.05 0.015
180–360 min 10.1  1.3 7.9  0.8 0.04 9.1  1.2 14.8  3.6 0.008
Glucose clearance
(ml/kg  min), 0–360
min
1.4  0.1 1.5  0.2 1.2  0.1 1.5  0.1 0.04 NS
0–180 min 1.4  0.1 1.4  0.1 1.2  0.1 1.4  0.1 NS
180–360 min 1.4  0.1 1.5  0.2 1.2  0.1 1.6  0.1 0.007 0.06
ISR (pmol/min), 0–360 min 1665  151 1951  120a 0.01 1155  74 1492  80a 0.01 NS
ISI (Matsuda)
0–180 min 3.5  0.4 4.7  0.5 0.07 3.3  0.6 4.4  1.0 NS
0–360 min 4.0  0.5 5.4  0.6 0.10 3.7  0.7 4.2  1.0 NS
Insulin secretion index ISR/
(G  ISI)	
0–180 min 447  97 749  118 0.02 262  50 612  151 0.04 NS
0–360 min 563  126 951  167 0.04 296  63 618  143 0.01
Splanchnic glucose retention
(g), 0–360 min
11.3  5.4 12.3  4.4 4.5  1.1 17.6  5.3 0.05 NS
Urinary glucose excretion
(g), 0–360 min
7.4  0.0 2.1  0.7a 0.0003 7.5  1.4 3.4  0.3a 0.02 NS
Urinary glucose excretion
(mol/min  kg), 0–360
min
1.23  0.14 0.34  0.1 0.0002 1.37  0.31 0.62  0.09 0.03 NS
BMI, Body mass index; ISI, insulin sensitivity index; G, glucose.
a P  0.05 vs. basal.
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vs. baseline MTT and mean postmeal PG in protocol I).
The incremental plasma glucose response was markedly
reduced (P  0.0001) in protocol II (exenatide given in
morning ofMTT) vs.protocol I (exenatide not given) (Fig.
1). Neither FPI nor mean plasma insulin concentration
during themeal (Table 1) changed significantly during the
postexenatideMTT (Fig. 1). Fasting plasma glucagon and
plasma glucagon during the meal were similar in pre- and
postexenatide studies (Table 1 and Fig. 1).
Fasting insulin secretory rate tended to increase (P
value NS) (Table 1), whereas ISR during the meal in-
creased significantly (1155 74 to 1492 80 pmol/min,
P 0.02) (Table 1 and Fig. 1) after exenatide. The insulin
secretion/insulin resistance (disposition) index increased
2-fold (296  63 to 618  143, P  0.02) during the
postexenatide meal test (Table 1).
Neither theMatsuda index of insulin sensitivity nor the
glucose clearance changed significantly during the meal
test performed after exenatide (Table 1).
Glucose kinetics (Table 1)
Both the RaT in the systemic circu-
lation (23.7 1.8 to 14.3 2.5 mol/
min  kg) as well as RaO (19.8 1.2 to
9.5 3.5 mol/min  kg) were reduced
(P 0.05) during the initial 0–180min
during the meal after exenatide treat-
ment (Table 1). From 180–360 min,
both RaT and RaO increased to values
above those in the preexenatide MTT
(Table 1), yet the plasma glucose con-
centration during this time period rose
only slightly (Fig. 1). After 2 wk of ex-
enatide, basal rate of EGP decreased
from 13.4  1.5 to 10.7  0.8 mol/
kg  min (P  0.05). When all 17 sub-
jects (protocols I and II) were consid-
ered collectively, the decline in FPG
correlated strongly with the decline in
EGP (r  0.74; P  0.001). After 14 d
of exenatide, themean rate of EGP dur-
ing MTT was similar to the preex-
enatide MTT. Unlike the RaO, which
increased from 180–360 min, EGP de-
clined, thusminimizing the rise in plasma
glucose concentration from 180–360
min.During thepostexenatide study,glu-
cose clearance increased modestly (P 
0.04) (Table 1) and urinary glucose ex-
cretion decreased (P 0.03) (Table 1).
During 0–360 min, approximately
75% (57.4  5.3 of 75 g) of the oral
glucose load appeared in the systemic
circulation (compared with 70.5  1.1 g during the pre-
exenatide study). Thus, 17.6 g of the ingested glucose was
retainedwithin the splanchnic regionduring the6-hMTT.
Exenatide was well tolerated in both protocols I and II.
Six of 17 T2DM patients experienced mild nausea, which
disappeared by the end of the 2-wk treatment period. One
sulfonylurea-treated patient developed mild symptomatic
hypoglycemia (FPG45mg/dl), and the sulfonylureawas
discontinued.
Discussion
In both protocols I and II, 2 wk of exenatide treatment
improved glycemic control in T2DMby reducing both the
fasting and postprandial plasma glucose concentrations
(Table 1 and Fig. 1) without change in body weight. In
protocols I and II combined, the decrease in FPG corre-
lated positively with the reduction in basal EGP (r 0.74;
FIG. 1. Plasma glucose, insulin, C-peptide, and glucagon concentrations in T2DM patients
after ingestion of a mixed meal before and after 2 wk of exenatide administration. In protocol
I, but not in protocol II, exenatide was administered before the repeat meal. See Table 1 for
statistical analysis.
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P 0.001). In neither protocol I nor protocol II was there
a significant increase in fasting plasma insulin concentra-
tion despite the significant reduction in basal EGP. How-
ever, the fasting ISR tended to increase in both protocols
I and II. We interpret these findings as follows. Initially,
exenatide augments insulin secretion leading to decreased
EGP. As basal EGP falls over the subsequent 2 wk, FPG
declines because basal EGP is the primary determinant of
FPG (1). The decline in FPG leads to a decrease in fasting
plasma insulin concentration, explaining the failure to ob-
serve any increase in FPI or any correlation between fast-
ing FPI and reduced EGP. Because the basal HIRI im-
proved by 33% (Table 1), an unchanged FPI
concentrationwas able tomaintain a reduced rate of basal
EGP. In contrast, when exenatide was given on d 14 (pro-
tocol II), fastingplasma insulin tended to increase, and this
may have obscured any change in HIRI. Furthermore, al-
though a small but significant decrease in EGP was noted
in protocol II, the large variation in plasma insulin con-
centration (
40%), which directly affects calculation of
the HIRI, also could have contributed to the failure to
observe a decline in HIRI. Because fasting plasma gluca-
gon concentration did not change and because glucagon
extraction by the liver is minimal (10%), reduced
plasma glucagon concentration cannot account for the
decrease in basal EGP. A direct inhibitory effect of ex-
enatideonHGP, as recently suggested, cannot be excluded
(4). The failure to observe a reduction in plasma glucagon
concentration after exenatide administration before the
MTT differs from previous results by us (8) and may be
related to the route (iv vs. sc) and/or duration (acute vs. 2
wk) of exenatide administration.
In protocol I (no exenatide given in the morning of the
repeat MTT), the decrement in FPG (by 2.6 mol/liter)
accounted for all of the decrement in postmeal plasma
glucose concentration (Fig. 1). In protocol II (exenatide
given before the repeat MTT), the increment in postmeal
plasma glucose concentration was markedly reduced by
more than 90% compared with protocol I, and this was
due primarily to a marked decrease in the RaO in the
systemic circulation (Table 1).
In contrast to the basal HIRI, which was significantly
improved after 2 wk of exenatide, we did not observe any
significant effect of exenatide on peripheral tissue insulin
sensitivity as assessed by the Matsuda insulin sensitivity
index. A small increase in glucose clearance during the
MTT was observed when exenatide was given immedi-
ately before the meal (protocol II) but not when the last
dose of exenatide was given on the previous evening (pro-
tocol I) (Table 1).However, the difference in glucose clear-
ance during the MTT was not significant between proto-
cols I and II andmayrepresent anartifactof the calculation
due to the greater decline in postmeal plasma glucose con-
centration in protocol II. The failure to observe a major
effect of exenatide on insulin-mediated glucose disposal is
consistent with previous observations (5, 8, 13, 23–26).
Because urinary glucose excretion was small and de-
creased only slightly (by 0.7–0.9 mol/kg  min) after ex-
enatide in protocols I and II (Table 1), changes in renal
glucosuria cannot explain the improvement in FPG or
meal glucose tolerance after exenatide in T2DM.
T2DM subjects have reduced circulating GLP-1 levels
(3, 27) and a marked defect in the ability of the liver to
dispose of an ingested glucose load (18, 28–30). The lack
of effect of exenatide on gastric emptying in protocol I
allowed us to examine the effect of this GLP-1 analog on
splanchnic (liver plus gastrointestinal tissues) glucose up-
take. In the postexenatide study, splanchnic glucose re-
tention was similar to that in the preexenatide study
(12.3  4.4 vs. 11.3  5.4 g, P value NS). Thus, GLP-1
does not appear to be the long sought after gut factor that
explains enhanced SGU after glucose ingestion (29, 30)
and deficiency of which accounts for impaired SGU after
oral glucose in T2DM (29–31). This conclusion may ap-
pear to be at variance with recently published studies in
dogs (6, 14–16). However, in addition to species differ-
ences (man vs. dog), there were a number of other differ-
ences between the present and previous studies. In the
studies by Johnson et al. (6) and Dardevet et al. (14), net
hepatic glucose balance (HGB) (sum of HGP and HGU)
was measured, GLP-1 was infused directly into the portal
vein, and the increase in net HGBwas quite small and not
significant in one of the two studies (6). In the study by
Edgerton et al. (15), both glucose and GLP-1 were deliv-
ered into the portal vein and vildagliptin (dipeptidyl pep-
tidase-4 inhibitor) was given orally. Net HGB increased
after vildagliptin in association with a rise in plasma
GLP-1 and insulin levels and a decrease in plasma gluca-
gon concentration.Whether the increase innetHGB is due
to increased HGU or decreased HGP and what role vilda-
gliptin per se vs. increased GLP-1 vs. the changes in plasma
insulin and glucagon played in the increase in net HGB is
difficult to determine. Ionut et al. (16) also suggested that
GLP-1may augmentHGU, but nomeasures ofHGU,HGP,
ornetHGBweremade toexplain the increase inwhole-body
glucose clearance after intraportal GLP-1 infusion.
One could argue that the lack of stimulatory effect of
exenatide on SGU (protocol I) is not surprising, because
exenatide was not administered on the day of MTT and
plasma exenatide levels were undetectable. In an attempt
to examine this question, we quantitated splanchnic glu-
cose retention (sum of SGU and gastric retention of glu-
cose) when exenatide was administered in the morning of
the mixed meal (protocol II). Of the 75-g glucose load,
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only 57.4 g, or 73%of the administered glucose load, was
recovered in the systemic circulation (RaO).However, be-
cause exenatide delays gastric emptying (8), it is not pos-
sible to determine whether the decrease in RaO is ex-
plained by increased SGUor delayed gastric emptying and
sequestration of the ingested glucose within the stomach.
Because the inhibitory effect of exenatide on gastric emp-
tying is related to the prevailing plasma exenatide concen-
tration and is not observed until pharmacological levels of
the GLP-1 analog are reached (32), it will be difficult in
man to evaluate the effect of exenatide on SGU.
GLP-1 and GLP-1-mimetic agents are potent insulin
secretagogues (2–3, 7, 23, 27, 33). In this study, the insu-
lin secretion/insulin resistance index increased by 69% in
protocol I compared with 109% in protocol II. Thus, in
protocol II, exenatide still exerted a stimulatory effect on
insulin secretion 16 h after administration, although the
stimulatory effect on insulin secretion already had begun
to wane by the following morning. Because exenatide
treatment for 2 wk similarly reduced the fasting plasma
glucose concentration in both protocols I and II (Table 1),
it is unlikely that an improvement in glucotoxicity can
explain the persistent effect of exenatide on insulin secre-
tion 16 h after its administration. Bunck et al. (7) have
shown thatwithin 1month after stopping exenatide (after
treatment of T2DM patients for 1 yr), the stimulatory
effect of exenatide on insulin secretion had completely
disappeared. The precise time course of loss of effect of
exenatide on insulin secretion remains to be determined,
but the present results, when combined with those of
Bunck et al. (7), clearly document that the stimulatory
effect of exenatide on insulin secretion is lost within a
relatively short time after its discontinuation. Baseline an-
tidiabetic therapy (metformin, sulfonylurea, and met-
formin plus sulfonylurea) was similar in subjects in pro-
tocols I and II and, thus, cannot explain the stimulatory
effect of exenatide on insulin secretion. Lastly, the im-
provement in insulin secretion indexwith exenatide in the
three diet-treated subjectswas similar to that in oral agent-
treated individuals (data not shown).
In summary, the present study represents the first com-
prehensive evaluationof thephysiologicalmechanismsvia
which chronic exenatide treatment in man improves glu-
cose homeostasis after a typical mixed meal. Exenatide
treatment of T2DM subjects for 2 wk decreased the FPG
by inhibiting basal EGP. When exenatide is administered
immediately before the meal, there is a marked reduction
in postprandial glucose excursion due to a decrease in the
rate of appearance of ingested glucose in the systemic cir-
culation. We previously have shown that this decrease in
RaO is due to inhibition of gastric emptying (8). This ex-
plains themuch greater reduction in postmeal plasma glu-
cose excursion compared with studies performed when
exenatide is omitted before meal ingestion.
Acknowledgments
Address all correspondenceand requests for reprints to:RalphA.
DeFronzo,M.D.,DivisionofDiabetes,DepartmentofMedicine,
Mail Code 7886, 7703 Floyd Curl Drive, San Antonio, Texas.
E-mail: albarado@uthscsa.edu.
This work was supported by a grant from Amylin Pharma-
ceuticals and Eli Lilly.
Disclosure Summary: E.W., A.C., A.S.,M.F., P.Z., andN.M.
have nothing to declare. R.A.D. is a member of the Speaker’s
BureauofAmylin, Eli Lilly, andTakedaNorthAmerica; is on the
AdvisoryBoardofAmylin/Eli LillyAlliance,Roche,Takeda, and
Boehringer Ingelheim;has received researchgrants fromAmylin-
Lilly and Takeda; and is a Consultant for Bristol Myers Squibb,
Novartis, and Roche. E.C. is a member of the Speaker’s Bureau
of Pfizer and Sanofi-Aventis and is on the Advisory Board of
Amylin/Eli Lilly Alliance and Takeda. A.G. is a Consultant for
Roche.
References
1. Defronzo RA 2009 Banting Lecture. From the triumvirate to the
ominous octet: a new paradigm for the treatment of type 2 diabetes
mellitus. Diabetes 58:773–795
2. Holst JJ, Gromada J 2004 Role of incretin hormones in the regula-
tion of insulin secretion in diabetic and nondiabetic humans. Am J
Physiol Endocrinol Metab 287:E199–E206
3. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes
TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired
secretionof glucagon-likepeptide-1 in type2diabetic patients. JClin
Endocrinol Metab 86:3717–3723
4. Samson SL GE, Sathyanarayana P, Bajaj M, Chan L 2009 Exendin
4 down regulates gluconeogenic gene expression and gluconeogen-
esis in vivo and in isolated hepatocytes in vitro. Diabetes 58:A3
5. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA 2002 Lack
of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on
insulin action in non-diabetic humans. Diabetologia 45:1410–1415
6. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal
D, Cherrington AD 2008 Intraportally deliveredGLP-1, in the pres-
ence of hyperglycemia induced via peripheral glucose infusion, does
not changewhole body glucose utilization. Am J Physiol Endocrinol
Metab 294:E380–E384
7. BunckMC,DiamantM,Corne´rA,EliassonB,Malloy JL, Shaginian
RM,DengW,KendallDM,TaskinenMR,SmithU,Yki-Ja¨rvinenH,
Heine RJ 2009 One-year treatment with exenatide improves beta-
cell function, compared with insulin glargine, in metformin-treated
type 2 diabetic patients: a randomized, controlled trial. Diabetes
Care 32:762–768
8. CerveraA,Wajcberg E, SriwijitkamolA, FernandezM,ZuoP,Trip-
litt C, Musi N, DeFronzo RA, Cersosimo E 2008 Mechanism of
action of exenatide to reduce postprandial hyperglycemia in type 2
diabetes. Am J Physiol Endocrinol Metab 294:E846–E852
9. DeFronzo RA, Ratner RE, Han J, KimDD, FinemanMS, Baron AD
2005 Effects of exenatide (exendin-4) on glycemic control and
weight over 30 weeks in metformin-treated patients with type 2
diabetes. Diabetes Care 28:1092–1100
10. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH,
MacConell L 2008 Effects of exenatide versus sitagliptin on post-
prandial glucose, insulin and glucagon secretion, gastric emptying,
J Clin Endocrinol Metab, June 2011, 96(6):1763–1770 jcem.endojournals.org 1769
and caloric intake: a randomized, cross-over study. Curr Med Res
Opin 24:2943–2952
11. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M,
Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A,
Foley JE, DeFronzo RA 2007 The dipeptidyl peptidase IV inhibitor
vildagliptin suppresses endogenous glucose production and en-
hances islet function after single-dose administration in type 2 dia-
betic patients. J Clin Endocrinol Metab 92:1249–1255
12. Burcelin R, Da Costa A, Drucker D, Thorens B 2001 Glucose com-
petence of the hepatoportal vein sensor requires the presence of an
activated glucagon-like peptide-1 receptor.Diabetes 50:1720–1728
13. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D’Alessio DA 2003
Effects of GLP-1-(7–36)NH2, GLP-1-(7–37), and GLP-1-(9–
36)NH2 on intravenous glucose tolerance and glucose-induced in-
sulin secretion in healthy humans. J Clin Endocrinol Metab 88:
1772–1779
14. Dardevet D, Moore MC, DiCostanzo CA, Farmer B, Neal DW,
Snead W, Lautz M, Cherrington AD 2005 Insulin secretion-inde-
pendent effects of GLP-1 on canine liver glucose metabolism do not
involve portal veinGLP-1 receptors.AmJPhysiolGastrointest Liver
Physiol 289:G806–G814
15. Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang
X, Duttaroy A, Cherrington AD 2009 Inhibition of dipeptidyl pep-
tidase-4 by vildagliptin during glucagon-like peptide 1 infusion in-
creases liver glucose uptake in the conscious dog. Diabetes 58:243–
249
16. Ionut V, ZhengD, Stefanovski D, BergmanRN 2008 Exenatide can
reduce glucose independent of islet hormones or gastric emptying.
Am J Physiol Endocrinol Metab 295:E269–E277
17. Blase E, Taylor K, Gao HY, Wintle M, Fineman M 2005 Pharma-
cokinetics of an oral drug (acetaminophen) administered at various
times in relation to subcutaneous injection of exenatide (exendin-4)
in healthy subjects. J Clin Pharmacol 45:570–577
18. Ferrannini E, Simonson DC, Katz LD, Reichard G Jr, Bevilacqua S,
Barrett EJ, Olsson M, DeFronzo RA 1988 The disposal of an oral
glucose load in patients with non-insulin-dependent diabetes. Me-
tabolism 37:79–85
19. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R,
Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA
2007 Relationship between hepatic/visceral fat and hepatic insulin
resistance in nondiabetic and type 2 diabetic subjects. Gastroenter-
ology 133:496–506
20. Hovorka R, Soons PA, Young MA 1996 ISEC: a program to cal-
culate insulin secretion. Comput Methods Programs Biomed 50:
253–264
21. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, De-
Fronzo RA 2006 Insulin secretion and action in subjects with im-
paired fasting glucose and impaired glucose tolerance: results from
the Veterans Administration Genetic Epidemiology Study. Diabetes
55:1430–1435
22. MatsudaM,DeFronzoRA 1999 Insulin sensitivity indices obtained
fromoral glucose tolerance testing: comparisonwith the euglycemic
insulin clamp. Diabetes Care 22:1462–1470
23. D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW 1994 Glucagon-
like peptide 1 enhances glucose tolerance both by stimulation of
insulin release and by increasing insulin-independent glucose dis-
posal. J Clin Invest 93:2263–2266
24. Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG,
SchmitzO 1996GLP-1 does not not acutely affect insulin sensitivity
in healthy man. Diabetologia 39:1227–1232
25. Ryan AS, Egan JM, Habener JF, Elahi D 1998 Insulinotropic hor-
mone glucagon-like peptide-1-(7–37) appears not to augment insu-
lin-mediated glucose uptake in youngmen during euglycemia. J Clin
Endocrinol Metab 83:2399–2404
26. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA 2000 Effect of
glucagon-like peptide 1(7–36) amide on glucose effectiveness and
insulin action in people with type 2 diabetes. Diabetes 49:611–617
27. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001 Re-
duced postprandial concentrations of intact biologically active glu-
cagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609–
613
28. BasuA, BasuR, Shah P,VellaA, JohnsonCM,NairKS, JensenMD,
SchwenkWF,RizzaRA2000Effects of type 2 diabetes on the ability
of insulin and glucose to regulate splanchnic and muscle glucose
metabolism: evidence for a defect in hepatic glucokinase activity.
Diabetes 49:272–283
29. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, Felig P 1978
Influence of hyperinsulinemia, hyperglycemia, and the route of glu-
cose administration on splanchnic glucose exchange. Proc Natl
Acad Sci USA 75:5173–5177
30. Ferrannini E, Wahren J, Felig P, DeFronzo RA 1980 The role of
fractional glucose extraction in the regulation of splanchnic glucose
metabolism in normal and diabetic man. Metabolism 29:28–35
31. DeFronzo F, Ferrannini E, Wahren J, Felig P 1978 Lack of a gas-
trointestinal mediator of insulin action in maturity-onset diabetes.
Lancet 2:1077–1079
32. Triplitt C, DeFronzo, RA 2006 Exenatide: first in class incretin
mimetic for the treatment of type 2 diabetes mellitus. Exp Rev En-
docirnol Metab 1:329–341
33. Kjems LL, Holst JJ, Vølund A, Madsbad S 2003 The influence of
GLP-1 on glucose-stimulated insulin secretion: effects on -cell sen-
sitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386
1770 Cersosimo et al. Exenatide and Glucose Metabolism in T2DM J Clin Endocrinol Metab, June 2011, 96(6):1763–1770
